These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 7893855)

  • 1. Acute challenge ERP as a prognostic of stimulant therapy outcome in attention-deficit hyperactivity disorder.
    Young ES; Perros P; Price GW; Sadler T
    Biol Psychiatry; 1995 Jan; 37(1):25-33. PubMed ID: 7893855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The value of cognitive evoked potentials in assessing the effectiveness of methylphenidate treatment in children with attention deficit hyperactivity disorder].
    Idiazábal-Alecha MA; Rodríguez-Vázquez S; Guerrero-Gallo D; Vicent-Sardinero X
    Rev Neurol; 2005 Jan; 40 Suppl 1():S37-42. PubMed ID: 15736091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of methylphenidate on auditory event related potential in boys with attention deficit hyperactivity disorder.
    Ozdag MF; Yorbik O; Ulas UH; Hamamcioglu K; Vural O
    Int J Pediatr Otorhinolaryngol; 2004 Oct; 68(10):1267-72. PubMed ID: 15364497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responses to methylphenidate in adolescent AD/HD: evidence from concurrently recorded autonomic (EDA) and central (EEG and ERP) measures.
    Hermens DF; Williams LM; Clarke S; Kohn M; Cooper N; Gordon E
    Int J Psychophysiol; 2005 Oct; 58(1):21-33. PubMed ID: 15936104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of methylphenidate on response inhibition and the event-related potential of children with attention deficit/hyperactivity disorder.
    Broyd SJ; Johnstone SJ; Barry RJ; Clarke AR; McCarthy R; Selikowitz M; Lawrence CA
    Int J Psychophysiol; 2005 Oct; 58(1):47-58. PubMed ID: 15925419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sources of auditory selective attention and the effects of methylphenidate in children with attention-deficit/hyperactivity disorder.
    Kemner C; Jonkman LM; Kenemans JL; Böcker KB; Verbaten MN; Van Engeland H
    Biol Psychiatry; 2004 Apr; 55(7):776-8. PubMed ID: 15039009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
    Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
    Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Studies of evoked potentials in children with the syndrome of attention deficit and hyperactivity].
    Smeyers P
    Rev Neurol; 1999 Feb; 28 Suppl 2():S173-6. PubMed ID: 10778509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication.
    Schertz M; Adesman AR; Alfieri NE; Bienkowski RS
    Pediatrics; 1996 Oct; 98(4 Pt 1):763-9. PubMed ID: 8885958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute effects of methylphenidate on performance during the Test of Variables of Attention in children with attention deficit/hyperactivity disorder.
    Huang YS; Chao CC; Wu YY; Chen YY; Chen CK
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):219-25. PubMed ID: 17472588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute neuropsychological effects of methylphenidate in stimulant drug-naïve boys with ADHD II--broader executive and non-executive domains.
    Rhodes SM; Coghill DR; Matthews K
    J Child Psychol Psychiatry; 2006 Nov; 47(11):1184-94. PubMed ID: 17076758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restoration of disturbed intracortical motor inhibition and facilitation in attention deficit hyperactivity disorder children by methylphenidate.
    Buchmann J; Gierow W; Weber S; Hoeppner J; Klauer T; Benecke R; Haessler F; Wolters A
    Biol Psychiatry; 2007 Nov; 62(9):963-9. PubMed ID: 17719015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
    Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
    Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.
    Walitza S; Kämpf K; Artamonov N; Romanos M; Gnana Oli R; Wirth S; Warnke A; Gerlach M; Stopper H
    Toxicol Lett; 2009 Jan; 184(1):38-43. PubMed ID: 19015014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder.
    Nikles CJ; Mitchell GK; Del Mar CB; Clavarino A; McNairn N
    Pediatrics; 2006 Jun; 117(6):2040-6. PubMed ID: 16740846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of methylphenidate in ADHD adults on target evaluation processing reflected by event-related potentials.
    Ohlmeier MD; Prox V; Zhang Y; Zedler M; Ziegenbein M; Emrich HM; Dietrich DE
    Neurosci Lett; 2007 Sep; 424(3):149-54. PubMed ID: 17723273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attention-deficit/hyperactivity disorder: use of cognitive evoked potential (P300) to predict treatment response.
    Sangal RB; Sangal JM
    Clin Neurophysiol; 2006 Sep; 117(9):1996-2006. PubMed ID: 16890481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.